Patient Start Form
PatientsHCPs
This site is for US Healthcare Professionals only.
[Left] Woman contemplating the luck her four-leaf clover necklace could bring her. [Right] Four-leaf clover necklace left behind.

Mechanism of Action


Not an actual patient. Individual results will vary. 

ILARIS addresses a key component in the primary inflammatory pathway of Still’s disease by targeting IL-1β1-3

ILARIS blocks inflammatory signaling that impacts both systemic and arthritic inflammation1,4,5

Inflammatory signaling blocking. Systemic and arthritic inflammatory signaling blocked.

Preclinical activity may not correlate with outcomes.

ILARIS is a recombinant, human anti-human—IL-1β monoclonal antibody1,2

ILARIS Binds To:ILARIS Does Not Bind To:
  • Human IL-1β and neutralizes its activity by blocking its interaction with the IL-1 receptor
  • IL-1α 
  • IL-1 receptor antagonist
References: 1. Ilaris. Prescribing information. Novartis Pharmaceuticals Corp. 2. Macovei LA, Burlui A, Bratoiu I, et al. Adult-onset Still’s disease—a complex disease, a challenging treatment. Int J Mol Sci. 2022;23(21):12810. doi:10.3390/ijms232112810 3. Galozzi P, Bindoli S, Doria A, Sfriso P. Progress in biological therapies for adult-onset Still’s disease. Biologics. 2022;16:21-34. doi:10.2147/BTT.S290329. eCollection 2022 4. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011;63(2):314-324. doi:10.1002/art.30105 5. Church LD, Cook GP, and McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34-42. doi:10.1038/ncprheum0681